1. Main findings and recommendations from the UNIDO study on the pharmaceutical sector in Zimbabwe
Domestication of TRIPs Flexibilities in National IP Legislation for Strengthening Access to Medicines in Zimbabwe 23 January 2014

2. Introduction and Background Main Findings Recommendations
Presentation Outline
Introduction and Background
Main Findings
Recommendations
Current status
11/29/2018

3. Introduction and Background
Study title: Pharmaceutical Sector Profile Zimbabwe
Commissioned by the United Nations Industrial Development Organization (UNIDO) as part of the Global UNIDO Project:
Strengthening the local production of essential generic drugs in least developed and developing countries
Study was prepared in 2010 by UNIDO consultant, Chris Chitemerere, under the supervision of the UNIDO project team
Study was published in 2011
11/29/2018

4. Introduction and Background
The project produced a series of reports covering different countries
The series of reports describe the local pharmaceutical industry in individual countries
Main purpose was to provide a comprehensive picture of the status and operating environment of the pharmaceutical sector and are designed to assist national level stakeholders and inform discussions on how local production fits into the strategy for improved supply of medicines
Also designed to feed into the ongoing debate among the international development community on the local manufacturing of generic medicines
11/29/2018

5. Introduction and Background
The study profiled four local manufacturing companies:
CAPS Private limited
Datlabs
Plus Five
Varichem
Others (not interested)
Study had a strong emphasis on generic essential medicines used in the management of HIV/AIDS, malaria and tuberculosis
11/29/2018

6. Main Findings
The pharmaceutical market in Zimbabwe is a relatively modest one with a balanced set of supply and demand fundamentals
Although there is a huge need for medicines, there still remains a huge funding gap to meet the needs
On the supply side, local generic medicines manufacturing companies have relatively balanced product portfolios and able to supply 47% of items on the Essential Drugs List for Zimbabwe
However, product portfolios are aged and highly commoditized resulting in poor export performance and intense competition from foreign suppliers especially those of Indian origin
11/29/2018

7. Main Findings
Perceived conflict between industrial policy, which aims to promote local manufacture, and health policy, which aims for maximum access to essential medicines (Now resolved)
Business environment not conducive for the development of the local pharma manufacturing industry e.g.
Funding
Low disposable incomes
Antiquated property, plant and equipment
Unfavourable tariff structure
High cost of inputs and utilities
11/29/2018

8. Main Findings
The Patent Act of 1996, as amended in 2002, in need of a complete overhaul in order to safeguard interests of generic medicines producers
Zimbabwe medicines regulatory machinery relatively strong when compared with that of its counterparts in the African region
Funding of NatPharm almost non-existent, posing viability challenges for local manufacturers
Pharmaceutical value chain weak especially in the area of R&D
11/29/2018

9. Key Recommendations
Recommendations at national, sector and individual company level
Policy issues need to be addressed urgently in order to create a conducive business environment for local pharma manufacturing industry
Development strategy for the pharma sector
Funding of the health sector
Local pharma industry needs to embark on strategic partnerships in order to strengthen pharmaceutical value chain
11/29/2018

10. Key Recommendations
Support of individual local pharma companies through development institutions for specific projects
Support for industry at association level in the form of training and other capacity building initiatives
11/29/2018

11. Current Status MCAZ Register therapeutic profile
Registrations as at August 2013
Essential Medicines Capacity/Deficits
Importance of local funding – a South African Example
Global Fund Purchases and Disbursements
Patent Searches
11/29/2018

12. URL for Zim Pharma Profile
we_Pharma%20Sector%20Profile_032011_Ebook.pdf
11/29/2018

13. THANK YOU
11/29/2018